---
title: "Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer"
description: "This phase II trial studies the side effects of and how well neratinib works in treating older patients with stage IV HER2-positive breast cancer. Neratini"
url: "https://www.clareohealth.com/clinical-trials/NCT02673398"
---

This phase II trial studies the side effects of and how well neratinib works in treating older patients with stage IV HER2-positive breast cancer. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

## Key Facts

**ID:** NCT02673398
**Status:** COMPLETED
**Phase:** PHASE2
**Type:** INTERVENTIONAL
**Enrollment:** 25
**Sponsor:** City of Hope Medical Center

## Detailed Description

PRIMARY OBJECTIVES: I. To estimate the safety and tolerability of neratinib in adults age 60 or older with locally advanced or metastatic HER2 over-expressing breast cancer. SECONDARY OBJECTIVES: I. To describe the full toxicity profile including all grade toxicities measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0. II. To estimate the rate of all grades of gastrointestinal (GI) toxicities such as diarrhea, nausea, and vomiting. III. To estimate the rate of dose reduction, delays and discontinuation related to study drug. IV. To describe pharmacokinetic parameters of neratinib in adults 60 and older. V. To estimate overall response rate (ORR) and clinical benefit rate (CBR) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. VI. To estimate event free survival (EFS), progression-free survival (PFS) and overall survival (OS). VII. To evaluate the role of cancer-specific geriatric assessment tool in predicting treatment toxicities. VIII. To estimate adherence rate to neratinib in older adults (percentage of doses of neratinib taken). IX. To explore the association of pharmacokinetic (PK) parameters and geriatric assessment findings. X. To explore if serum biomarkers of aging (interleukin \[IL\]-6, C-reactive protein \[CRP\], and D-dimer) are associated with treatment toxicities. OUTLINE: Patients receive neratinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days and then periodically thereafter.

## Conditions

- HER2 Positive Breast Carcinoma
- Stage IV Breast Cancer AJCC v6 and v7

## Interventions

**OTHER: Comprehensive Geriatric Assessment**
Ancillary studies

**OTHER: Laboratory Biomarker Analysis**
Correlative studies

**DRUG: Neratinib**
Given PO

**OTHER: Pharmacological Study**
Correlative studies

## Eligibility

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance 0-2 * Life expectancy of greater than 12 weeks * Histologically or cytologically proven metastatic brea…

## Who Can Participate

**Minimum age:** 60

**Sex:** ALL

**Accepts healthy volunteers:** No

## Study Locations

- City of Hope Corona, Corona, California, United States
- City of Hope Medical Center, Duarte, California, United States
- City of Hope Antelope Valley, Lancaster, California, United States
- City of Hope Mission Hills, Mission Hills, California, United States
- City of Hope Rancho Cucamonga, Rancho Cucamonga, California, United States
- City of Hope South Pasadena, South Pasadena, California, United States
- City of Hope West Covina, West Covina, California, United States

## Contact Information

## Important Dates

**Study start:** December 2, 2016

**Completion date:** September 22, 2022

**Last updated:** June 18, 2023

## Collaborators

- National Cancer Institute (NCI)

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02673398)
